<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01657214</url>
  </required_header>
  <id_info>
    <org_study_id>TED12337</org_study_id>
    <secondary_id>U1111-1126-7527</secondary_id>
    <nct_id>NCT01657214</nct_id>
  </id_info>
  <brief_title>Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients</brief_title>
  <acronym>SARMETA</acronym>
  <official_title>Phase I, Dose Escalation Study of Safety, Pharmacokinetic and Pharmacodynamic of SAR125844 Administered Weekly as Intravenous Infusion in Asian Adult Patients With Advanced Malignant Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      In the dose escalation: to determine the maximum tolerated dose (MTD) of SAR125844.&#xD;
&#xD;
      In the expansion cohort: to evaluate the preliminary anti-tumoral effect of SAR125844 in&#xD;
      patients with measurable and MET gene amplification (including gastric cancer patients).&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      To characterize and confirm the global safety profile of SAR125844 including cumulative&#xD;
      toxicities.&#xD;
&#xD;
      To assess preliminary antitumor activity of SAR125844. To explore the pharmacodynamic effects&#xD;
      (PDy) of SAR125844. To evaluate the pharmacokinetic profile of SAR125844. To explore the&#xD;
      relationship of MET gene amplification status with antitumor effects.&#xD;
&#xD;
      To evaluate other pharmacodynamic biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For both cohorts, escalation and expansion, the duration of the study for one patient will&#xD;
      include a period for inclusion of up to 3 weeks and a 4-week treatment cycle(s).The patient&#xD;
      may continue treatment until disease progression, unacceptable toxicity or willingness to&#xD;
      stop, followed by a minimum of 30-days follow-up.&#xD;
&#xD;
      If a patient treated in dose escalation part or in an expansion cohort, continues to benefit&#xD;
      from the treatment at the time of Clinical Study Report, the patient can continue study&#xD;
      treatment for a maximum of 1 year and will continue to undergo all assessments as per the&#xD;
      study flowchart. Such patients will be followed at least until 30 days after the last IMP&#xD;
      administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>- DOSE ESCALATION To determine the maximum tolerated dose (MTD) of SAR125844</measure>
    <time_frame>At d28 of Cycle 1 of each treated patient, DLT is assessed</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>- EXPANSION Cohort To evaluate the preliminary anti-tumoral effect of SAR125844</measure>
    <time_frame>Antitumor activity is assessed at the end of Cycle 1, then every 2 cycles up to treatment discontinuation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with treatment emergent events</measure>
    <time_frame>Up to a maximum of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter Cmax</measure>
    <time_frame>Up to a maximum of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter AUCs</measure>
    <time_frame>Up to a maximum of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter CL</measure>
    <time_frame>Up to a maximum of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PD parameter ShedMET</measure>
    <time_frame>Up to a maximum of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PD parameter HGF</measure>
    <time_frame>Up to a maximum of 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Neoplasm Malignant</condition>
  <arm_group>
    <arm_group_label>Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAR125844 will be administered as weekly IV infusion. Four weekly administrations are considered as 1 cycle. The starting dose will be either 1 dose level (DL) below the highest cleared dose level in a European TED11449 ongoing study or DL4 (260 mg/m^2), if the highest cleared dose in TED11449 is &gt;340 mg/m^2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR125844</intervention_name>
    <description>Pharmaceutical form:Concentrate for solution&#xD;
Route of administration: intravenous</description>
    <arm_group_label>Dose escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patients with solid tumor for which no standard therapy is available.&#xD;
&#xD;
          -  At the recommended dose (expansion cohort): only patients with measurable disease and&#xD;
             MET gene amplification.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patient less than 20 years old.&#xD;
&#xD;
          -  ECOG performance status &gt;2.&#xD;
&#xD;
          -  Poor bone marrow reserve as defined by absolute neutrophils count &lt;1.5 x 10^9/L or&#xD;
             platelets &lt;100 x 10^9/L.&#xD;
&#xD;
          -  Poor organ function as defined by one of the following:&#xD;
&#xD;
          -  Total bilirubin &gt;1.5 x ULN.&#xD;
&#xD;
          -  AST, ALT, alkaline phosphatase &gt;2.5 x ULN or &gt;5 x ULN in case of documented liver&#xD;
             metastasis.&#xD;
&#xD;
          -  Serum creatinine &gt;1.5 x ULN, or serum creatinine between 1.0 and 1.5 x ULN associated&#xD;
             with calculated creatinine clearance &lt;60 mL/min.&#xD;
&#xD;
          -  Proteinuria &gt;500mg/24h.&#xD;
&#xD;
          -  Pregnant or breast-feeding women.&#xD;
&#xD;
          -  Sexually active (males and females) who do not agree to use medically acceptable&#xD;
             methods of contraception during the course of the study and for 3 months following&#xD;
             discontinuation of study drug.&#xD;
&#xD;
          -  Female patients of childbearing potential must have a negative pregnancy test at&#xD;
             screening.&#xD;
&#xD;
          -  Known or symptomatic brain metastasis (other than totally resected or previously&#xD;
             pre-irradiated and no progressive/relapsing) or lepto-meningeal carcinomatosis.&#xD;
&#xD;
          -  No resolution of any specific toxicities (excluding alopecia) related to any prior&#xD;
             anti-cancer therapy to grade ≤1 according to the NCI CTCAE v.4.03.&#xD;
&#xD;
          -  Wash out period of less than 3 weeks from previous antitumor therapy or any&#xD;
             investigational treatment,(and less than 6 weeks in case of prior nitrozo-urea and or&#xD;
             mitomycin C treatment).&#xD;
&#xD;
          -  Any surgery with major risk of bleeding performed less than 10 days prior to study&#xD;
             treatment administration.&#xD;
&#xD;
          -  Any other severe underlying medical conditions, which could impair the ability to&#xD;
             participate in the study.&#xD;
&#xD;
          -  Patients treated with potent CYP3A inhibitor.&#xD;
&#xD;
          -  Patients treated with potent and moderate CYP3A inducers.&#xD;
&#xD;
          -  Known hypersensitivity or any adverse event related to the study drug excipient&#xD;
             (Captisol®).&#xD;
&#xD;
          -  Prior treatment with any MET inhibitor compound (selective or not).&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 392001</name>
      <address>
        <city>Kashiwa-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392004</name>
      <address>
        <city>Suita-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392002</name>
      <address>
        <city>Sunto-Gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392003</name>
      <address>
        <city>Takatsuki-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410001</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410004</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410003</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410002</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>July 24, 2012</study_first_submitted>
  <study_first_submitted_qc>August 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2012</study_first_posted>
  <last_update_submitted>February 16, 2016</last_update_submitted>
  <last_update_submitted_qc>February 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

